Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Upcoming 2016 Investor Conference Presentation

Key Takeaway: Regeneron Announces Upcoming 2016 Investor Conference Presentation

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,July 18, 2016/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast a management presentation at the following investor conference:
• 36thAnnual Canaccord Genuity Growth Conference at11:30 a.m. Eastern TimeonThursday, August 11, 2016
The session may be accessed through the Company's web site,www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentation will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ:REGN) is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer and infectious diseases. For additional information about the company, please visitwww.regeneron.comor follow @Regeneron on Twitter.
Contact Information:
Investor Relations Corporate Communications
Manisha Narasimhan, Ph.D. Hala Mirza
914.847.5126 914.847.3422
[email protected] [email protected]
[email protected]
[email protected]
Last updated: Jul 18, 2016